A U.S. District Court Judge for the District of Columbia May 16 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate models” before they can be implemented, which ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving as later-line therapies to improve survival outcomes. The FDA has also ...